dvancing oncology therapies remains a challenging area of drug development. Many new agents, even if highly successful, can only be applied to certain sub-populations of patient groups. As certain oncology candidates move ahead, while many more are left behind, a plethora of clinical issues must be constantly examined and addressed to stay on top of your development plans. Stay ahead of the curve on Evaluation, Testing and Design strategies, tools and information that is necessary to make your key decisions.

Do you come across these kinds of questions?

* Were the correct decisions made early in the development process?
* Is my drug candidate poised to succeed because we carefully planned our trial design?
* Do we have the best team in place to advance this oncology candidate?
* Why are we lagging behind our competition?
* When is our next data point?
* How can we avoid delays and get better results?

ExL Pharma is proud to present Evaluating, Testing and Advancing Oncology Therapies, focusing on Trial Design, Testing Strategies, and Clinical Development Planning. Hear from Industry experts on the most pressing issues pharma and biotech face when conceiving, developing, and conducting their oncology clinical trials. Join thought-leaders and your fellow industry colleagues at this comprehensive industry event